

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:25:58 ON 05 JUN 2007

=> file ca

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CA' ENTERED AT 11:26:22 ON 05 JUN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 31 May 2007 VOL 146 ISS 24

FILE LAST UPDATED: 31 May 2007 (20070531/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s azithromycin and (citric or citrate)

3422 AZITHROMYCIN

87718 CITRIC

87914 CITRATE

L1 98 AZITHROMYCIN AND (CITRIC OR CITRATE)

=> s l1 and (salt or salts)

794096 SALT

613846 SALTS

L2 37 L1 AND (SALT OR SALTS)

=> s l2 and ph

1298434 PH

L3 10 L2 AND PH

=> d l3 1-10

L3 ANSWER 1 OF 10 CA COPYRIGHT 2007 ACS on STN

AN 146:128212 CA

TI Study on the selection of appropriate salt forming agents for azithromycin for injection

AU He, Qiying; Lu, Wanliang; Zhang, Qiang
 CS Department of Scientific Research, Guangdong Shunfeng Pharmaceutical Co.,
 Ltd., Shunde, 528300, Peop. Rep. China
 SO Zhongguo Kangshengsu Zazhi (2005), 30(4), 204-207
 CODEN: ZKZAEY; ISSN: 1001-8689
 PB Zhongguo Kangshengsu Zazhishe
 DT Journal
 LA Chinese

L3 ANSWER 2 OF 10 CA COPYRIGHT 2007 ACS on STN
 AN 145:363523 CA
 TI Multi-particulate, modified-release composition
 IN Patel, Ashish Anilbhai; Palaniswamy, Suresh; Davila, Pablo
 PA USA
 SO U.S. Pat. Appl. Publ., 10pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006210631	A1	20060921	US 2005-85671	20050321
	WO 2006102446	A2	20060928	WO 2006-US10457	20060320
	WO 2006102446	A3	20061221		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2005-85671	A	20050321		

L3 ANSWER 3 OF 10 CA COPYRIGHT 2007 ACS on STN
 AN 142:435862 CA
 TI Water-based composition undergoing reversible thermogelation
 IN Suzuki, Hidekazu
 PA Wakamoto Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 25 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005042026	A1	20050512	WO 2004-JP16500	20041101
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP	1681065	A1	20060719	EP 2004-799523	20041101
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS
 US 2006211599 A1 20060921 US 2006-414498 20060501
 PRAI JP 2003-371572 A 20031031
 WO 2004-JP16500 W 20041101
 RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 10 CA COPYRIGHT 2007 ACS on STN
 AN 142:43786 CA
 TI Addition salts of azithromycin and citric
 acid and process for preparing them
 IN Cosme, Gomez Antonio; Palomo Nicolau, Francisco Eugenio
 PA Quimica Sintetica, S.A., Spain
 SO PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004106355	A1	20041209	WO 2004-IB1728	20040526
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2220229	A1	20041201	ES 2003-1340	20030529
ES 2220229	B1	20051016		
CN 1798756	A	20060705	CN 2004-80014816	20040526
US 2007021359	A1	20070125	US 2005-558801	20051129
PRAI ES 2003-1340	A	20030529		
WO 2004-IB1728	W	20040526		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 10 CA COPYRIGHT 2007 ACS on STN
 AN 141:337695 CA
 TI Ophthalmic gel of azithromycin
 IN Wu, Wenyao; Wang, Ling
 PA Peop. Rep. China
 SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 5 pp.
 CODEN: CNXXEV
 DT Patent
 LA Chinese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CN 1410071	A	20030416	CN 2002-149186	20021128
PRAI CN 2002-149186		20021128		

L3 ANSWER 6 OF 10 CA COPYRIGHT 2007 ACS on STN
 AN 136:252482 CA
 TI Preparation of aqueous clear solution dosage forms with bile acids
 IN Yoo, Seo Hong
 PA USA
 SO U.S. Pat. Appl. Publ., 35 pp., Cont.-in-part of U. S. 6,251,428.
 CODEN: USXXCO
 DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002031558	A1	20020314	US 2001-778154	20010205
	US 6251428	B1	20010626	US 1999-357549	19990720
	US 2003186933	A1	20031002	US 2002-309603	20021204
	US 7166299	B2	20070123		
	US 2005158408	A1	20050721	US 2004-996945	20041124
	AU 2006203315	A1	20060824	AU 2006-203315	20060803
	US 2007072828	A1	20070329	US 2006-522162	20060915
PRAI	US 1998-94069P	P	19980724		
	US 1999-357549	A2	19990720		
	US 2000-180268P	P	20000204		
	AU 2001-36685	A3	20010205		
	US 2001-778154	A3	20010205		
	US 2004-996945	A2	20041124		

L3 ANSWER 7 OF 10 CA COPYRIGHT 2007 ACS on STN

AN 136:139859 CA

TI Manufacturing clear liquid pharmaceutical composition of azithromycin

IN Khamar, Bakulesh Mafatlal; Gumudavelli, Sridhar Krishnamurthy

PA Cadila Pharmaceuticals Limited, India

SO PCT Int. Appl., 10 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002007736	A1	20020131	WO 2001-IB1313	20010723
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	IN 2000MU00687	A	20060303	IN 2000-MU687	20000724
PRAI	IN 2000-MU687	A	20000724		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 10 CA COPYRIGHT 2007 ACS on STN

AN 135:157683 CA

TI Preparation of aqueous clear solution dosage forms with bile acids

IN Yoo, Seo Hong

PA USA

SO PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001056547	A2	20010809	WO 2001-US3745	20010205
	WO 2001056547	A3	20020718		
	WO 2001056547	B1	20030220		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2406930	A1	20010809	CA 2001-2406930	20010205

AU 200136685	A	20010814	AU 2001-36685	20010205
EP 1255566	A2	20021113	EP 2001-908862	20010205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004500378	T	20040108	JP 2001-556239	20010205
BR 2001008080	A	20060207	BR 2001-8080	20010205
RU 2277913	C2	20060620	RU 2002-123352	20010205
IN 2002DN00865	A	20050121	IN 2002-DN865	20020902
IN 2002DN00873	A	20050121	IN 2002-DN873	20020904
AU 2006203315	A1	20060824	AU 2006-203315	20060803
PRAI US 2000-180268P	P	20000204		
AU 2001-36685	A3	20010205		
WO 2001-US3745	W	20010205		

L3 ANSWER 9 OF 10 CA COPYRIGHT 2007 ACS on STN
AN 135:121657 CA
TI Composition for intestinal delivery
IN Vandenberg, Grant William
PA Aqua Solution Inc., Can.
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001054514	A1	20010802	WO 2001-CA73	20010125
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2396711	A1	20010802	CA 2001-2396711	20010125
	EP 1250056	A1	20021023	EP 2001-902185	20010125
	EP 1250056	B1	20060830		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003520862	T	20030708	JP 2001-555503	20010125
	NZ 520238	A	20040430	NZ 2001-520238	20010125
	AT 337712	T	20060915	AT 2001-902185	20010125
	NO 2002003464	A	20020924	NO 2002-3464	20020719
	IN 2002KN01950	A	20050311	IN 2002-KN1950	20020722
	IN 2002KN00950	A	20050916	IN 2002-KN950	20020722
	US 2003118547	A1	20030626	US 2002-181428	20021114
PRAI	US 2000-178318P	P	20000127		
	WO 2001-CA73	W	20010125		

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 10 CA COPYRIGHT 2007 ACS on STN
AN 134:168310 CA
TI Azithromycin polybasic acid sodium salt
IN He, Guangwei; Li, Jiaming; Zong, Guojun; Fan, Tianbei; Zhao, Shiguo
PA Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 12 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI	CN 1259520	A	20000712	CN 1998-124980	19981127
	CN 1096468	B	20021218		
PRAI	CN 1998-124980		19981127		

=> d 13 1-10 an ab

L3 ANSWER 1 OF 10 CA COPYRIGHT 2007 ACS on STN

AN 146:128212 CA

AB The appropriate salt was used for azithromycin for injection. Eight different kinds of acid react to azithromycin to obtain corresponding azithromycin salt solns. and freeze-dried products for injection. The pH, initial stability and hepatic toxicity test in animals were performed. The solns. of glutamic acid, lactic acid, tartaric acid, and aspartic acid with azithromycin were stable and its pH was in proper range. The pathol. studies revealed that the favorable salts were glutamate, citrate, aspartate, sulfate and hydrochloride, followed by dihydrogen phosphate, lactobionate and tartrate. Glutamic acid and aspartic acid are the appropriate acid for the preparation for azithromycin for injection.

L3 ANSWER 2 OF 10 CA COPYRIGHT 2007 ACS on STN

AN 145:363523 CA

AB A multi-particulate, modified-release pharmaceutical composition for the oral administration of an active ingredient to the colon, wherein said particles comprise: (a) a core comprising an active ingredient or a pharmaceutically acceptable salt or ester thereof, and optionally one or more excipients; (b) a first coating applied to the surface of the core, wherein said first coating is insol. in gastric juice and in intestinal juice below pH 7, but soluble in colonic intestinal juice; and (c) a second coating applied to the surface of the first coating. Core tablets containing mesalamine 400, microcryst. cellulose 50, lactose 28.0, copolyvidone 20.0, acetyl tri-Bu citrate 2.0 were coated with a composition containing methacrylic acid 35.0, 1.7% NH₃ solution 17.8, tri-Et citrate 24.5, and Lomicon talc 16.6 mg to obtain modified-release tablets.

L3 ANSWER 3 OF 10 CA COPYRIGHT 2007 ACS on STN

AN 142:435862 CA

AB A water-based composition undergoing reversible thermogelation comprises a conventional water-based composition undergoing reversible thermogelation and added thereto at least one substance enhancing thixotropic properties, preferably at least one of sugar alcs., lactose, carmellose or a pharmaceutically acceptable salt thereof, and cyclodextrin. This composition can be stored at room temperature and is convenient for carrying.

For example, an artificial tear was prepared containing Me cellulose, polyethylene glycol (Macrogol 4000), D-mannitol, Na citrate, aminoethylsulfonic acid, HCl (to pH 7.4), and distilled water.

L3 ANSWER 4 OF 10 CA COPYRIGHT 2007 ACS on STN

AN 142:43786 CA

AB Said addition salts have a molar ratio between azithromycin and citric acid such as to provide a pH comprised between 4.0 and 8.0 in a 10 % aqueous solution. The process for preparing said salts comprises: a) dissolving azithromycin in a solvent or mixture of solvents; b) adding citric acid; and c) isolating the product obtained by crystallization. The addition salts of azithromycin and citric acid are stable and soluble in aqueous medium, being useful antibacterial and antiprotozoan agents.

L3 ANSWER 5 OF 10 CA COPYRIGHT 2007 ACS on STN

AN 141:337695 CA

AB The ophthalmic gel is composed of 0.05-1% azithromycin or its medical salt, soluble macromol. polymer, pH regulator, antiseptic, iso-osmotic agent, antioxidant, surfactant, etc. The azithromycin medical salt is the one of HCl, sulfate, lactobionate, maleate, aspartate, citrate, malate, etc. The soluble macromol. polymer is carbopol, cellulose derivative, polyvinyl alc., etc.

L3 ANSWER 6 OF 10 CA COPYRIGHT 2007 ACS on STN

AN 136:252482 CA

AB Compns. for pharmaceutical and other uses comprise clear aqueous solns. of bile acids which do not form any detectable ppts. over selected ranges of pH values of the aqueous solution. The compns. comprise (i) water, (ii) a bile acid component in the form of a bile acid, bile acid salt, or a bile acid conjugated with an amine by an amide linkage; and (iii) either or both an aqueous soluble starch conversion product and an aqueous soluble non-starch polysaccharide. The composition remains in solution without forming a precipitate over a range of pH values and, according to one embodiment, remains in solution for all pH values obtainable in an aqueous system. The composition may further contain a pharmaceutical compound, such as insulin, heparin, bismuth compds., amantadine and rimantadine. For example, solution dosage forms that did not show any precipitation at any pH were prepared containing ursodeoxycholic acid (UDCA) 22 g, 1N NaOH 75 mL, chenodeoxycholic acid (CDCA) 3 g, maltodextrin 875 g, bismuth citrate 4 g, citric acid or lactic acid as needed, and purified water to make 1 L.

L3 ANSWER 7 OF 10 CA COPYRIGHT 2007 ACS on STN

AN 136:139859 CA

AB Azithromycin is a macrolide antibiotic used for treating infections. This is available in a solid oral dosage form. It is desirable to have a clear liquid formulation also for treating severe infections by i.v. administration of the drug. Currently, it is not possible to manufacture liquid preparation which is ready to use. As it is not soluble in water or other known solvents, for this purpose, it is being marketed as lyophilized preparation which is reconstituted prior to use. According to present invention, it is found that it is soluble in water at pH 5.0. The change in pH can be obtained by adding citric acid in a desired concentration. However, this solution is not stable, and ppts. are seen over the time. According to the present invention, this solution is stabilized by addition of sodium salts like sodium hydroxide, thereby changing its pH from 5.0 to 7.0. The solution so prepared remains clear and is stable for a longer period.

L3 ANSWER 8 OF 10 CA COPYRIGHT 2007 ACS on STN

AN 135:157683 CA

AB Compns. for pharmaceutical and other uses comprising clear aqueous solns. of bile acids which do not form any detectable ppts. over selected ranges of pH values of the aqueous solution and methods of making such solns. The compns. of the invention comprise water; a bile acid in the form of a bile acid, bile acid salt, or a bile acid conjugated with an amine by an amide linkage; and either or both an aqueous soluble starch conversion product and a aqueous soluble non-starch polysaccharide. The composition remains in solution without forming a precipitate over a range of pH values and, according to one embodiment, remains in solution for all pH values obtainable in an aqueous system. The composition, according to some embodiments, may further

contain a pharmaceutical compound in a pharmaceutically effective amount
Non-limiting examples of pharmaceutical compds. include insulin, heparin,
bismuth compds., amantadine and rimantadine. A syrup composition contained
ursodeoxycholic acid 20 g, 1N NaOH 60 mL, corn syrup solid 1050 g, Bi
citrate 4g, citric acid or lactic acid q.s. and purified
water to 1L.

L3 ANSWER 9 OF 10 CA COPYRIGHT 2007 ACS on STN

AN 135:121657 CA

AB The present invention relates to a new composition, use and method for oral
administration to a human or an animal of a physiol. active agent
comprising neutralizing agents to increase pH in the digestive
system to prevent denaturation, inhibitors of digestive enzymes to
substantially prevent enzymic digestion, and at least uptake-increasing
agents which increases intestinal absorption of a physiol. active agent, a
drug and/or a nutrient.

L3 ANSWER 10 OF 10 CA COPYRIGHT 2007 ACS on STN

AN 134:168310 CA

AB Azithromycin polybasic acid Na salt is
azithromycin salt of dihydrogen citrate,
hydrogen citrate, hydrogen tartrate, hydrogen succinate,
hydrogen fumarate, hydrogen oxalate, hydrogen maleate, sulfate, or
sulfite, the pH of its solution is 6.0-7.5, and they are prepared by
treatment of azithromycin with polybasic acid Na salt.
The tablet, capsule, granule, injection, infusion, and syrup of the
azithromycin polybasic acid Na salt are prepared

Refine Search

Search Results -

Terms	Documents
azithromycin near5 citric	12

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L2

**Refine Search**

Recall Text



Clear

Interrupt

Search History

DATE: Tuesday, June 05, 2007 [Purge Queries](#) [Printable Copy](#) [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L2</u>	azithromycin near5 citric	12	<u>L2</u>
<u>L1</u>	azithromycin near10 citric	16	<u>L1</u>

END OF SEARCH HISTORY